Elsevier Inc.

SHERPA: Unknown

People

  1. Chaft
    Chaft
  2. Wu
    Wu
  3. Gelblum
    Gelblum
  4. Shepherd
    Shepherd
  5. Gomez
    Gomez
  6. Shaverdian
    Shaverdian
  7. Offin
    Offin
  8. Zhang
    Zhang
  9. Paik
    Paik
  10. Yorke
    Yorke

Groups

  1. Department of Medicine (36)
  2. Radiation Oncology, Department of (36)
  3. Solid Tumor Oncology Division (36)
  4. Thoracic Oncology (36)
  5. Medical Physics (18)
  6. Sloan Kettering Institute Postdocs (17)
  7. Surgery (15)
  8. Radiotherapy Physics Service (14)
  9. Biostatistics Service (12)
  10. Epidemiology and Biostatistics (12)
Search Within
  1. "Abraham Wu"
  2. "Jamie Chaft"
Formats
  1. Meeting Abstract (24)
  2. Journal Article (12)
Groups
  1. Department of Medicine (36)
  2. Radiation Oncology, Department of (36)
  3. Solid Tumor Oncology Division (36)
  4. Thoracic Oncology (36)
  5. Medical Physics (18)
  6. Sloan Kettering Institute Postdocs (17)

More Groups

People
  1. Abraham Wu (36)
  2. Andreas Rimner (36)
  3. Jamie Chaft (36)
  4. Daphna Gelblum (25)
  5. Annemarie Shepherd (18)
  6. Daniel Gomez (16)

More People

Years
  1. 2024 (1)
  2. 2023 (2)
  3. 2022 (5)
  4. 2021 (4)
  5. 2020 (5)
  6. 2019 (2)

More Years

Publications
  1. International Journal of Radiation Oncology, Biology, Physics (19)
  2. Journal of Thoracic Oncology (8)
  3. Radiotherapy and Oncology (4)
  4. Advances in Radiation Oncology (2)
  5. Clinical Lung Cancer (2)
  6. Practical Radiation Oncology (1)

Results (36)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Exploring published and novel pre-treatment CT and PET radiomics to stratify risk of progression among early-stage non-small cell lung cancer patients treated with stereotactic radiation
    Journal Article

    Thor, M.; Fitzgerald, K.; Apte, A.; Hun Oh, J.; Iyer, A.; Odiase, O.; Nadeem, S.; Yorke, E. D.; Chaft, J.; Wu, A. J.; more...
    Radiotherapy and Oncology (2024)

    Fulltext@MSK | Save
  • A novel FDG PET and mean lung dose model to identify stage III NSCLC patients at high risk of developing early radiation pneumonitis
    Meeting Abstract

    Thor, M.; Shepherd, A. F.; Apte, A.; Gelblum, D.; Wu, A. J.; Simone, C. B. 2nd; Chaft, J.; Rimner, A.; Gomez, D. R.; Deasy, J. O.; more...
    International Journal of Radiation Oncology, Biology, Physics (2023)

    Fulltext@MSK | Save
  • Randomized phase 2 placebo-controlled trial of nintedanib for the treatment of radiation pneumonitis
    Journal Article

    Rimner, A.; Moore, Z. R.; Lobaugh, S.; Geyer, A.; Gelblum, D. Y.; Abdulnour, R. E. E.; Shepherd, A. F.; Shaverdian, N.; Wu, A. J.; Cuaron, J.; more...
    International Journal of Radiation Oncology, Biology, Physics (2023)

    Fulltext@MSK | Save
  • Planned interim analysis of a phase II trial of concurrent durvalumab and radiation therapy for locally advanced lung cancer
    Meeting Abstract

    Rimner, A.; Fitzgerald, K.; Iqbal, A. N.; Shepherd, A. F.; Gomez, D. R.; Shin, J. Y.; Gelblum, D. Y.; Hajj, C.; Albrecht, F.; Kotecha, R. R.; more...
    Journal of Thoracic Oncology (2022)

    Fulltext@MSK | Save
  • Biomarkers associated with pulmonary exacerbations in a prospective, placebo-controlled, randomized trial of nintedanib for the treatment of radiation pneumonitis
    Meeting Abstract

    Moore, Z. R.; Huang, X.; Lobaugh, S.; Geyer, A.; Gelblum, D.; Shepherd, A. F.; Shaverdian, N.; Wu, A. J.; Chaft, J.; Zauderer, M.; more...
    International Journal of Radiation Oncology, Biology, Physics (2022)

    Fulltext@MSK | Save
  • Tumor mutational burden predicts progression-free survival and local-regional control in locally advanced non-small cell lung cancer patients treated with chemoradiation and durvalumab
    Meeting Abstract

    Shaverdian, N.; Shepherd, A. F.; Offin, M.; Gelblum, D.; Wu, A. J.; Simone, C. B. 2nd; Schoenfeld, A. J.; Jones, D.; Rimner, A.; Chaft, J.; more...
    International Journal of Radiation Oncology, Biology, Physics (2022)

    Fulltext@MSK | Save
  • Effects of tumor mutational burden and gene alterations associated with radiation response on outcomes of postoperative radiation therapy in non-small cell lung cancer
    Journal Article

    Shaverdian, N.; Shepherd, A. F.; Li, X.; Offin, M.; Lengel, H. B.; Gelblum, D. Y.; Wu, A. J.; Simone, C. B. 2nd; Rimner, A.; Jones, D. R.; more...
    International Journal of Radiation Oncology, Biology, Physics (2022)

    Fulltext@MSK | Save
  • Pre-treatment immune status predicts disease control in NSCLCs treated with chemoradiation and durvalumab
    Journal Article

    Thor, M.; Shepherd, A. F.; Preeshagul, I.; Offin, M.; Gelblum, D. Y.; Wu, A. J.; Apte, A.; Simone, C. B. 2nd; Hellmann, M. D.; Rimner, A.; more...
    Radiotherapy and Oncology (2022)

    Fulltext@MSK | Save
  • The impact of durvalumab on local-regional control in stage III NSCLCs treated with chemoradiation and on KEAP1-NFE2l2-mutant tumors
    Journal Article

    Shaverdian, N.; Offin, M.; Shepherd, A. F.; Simone, C. B. 2nd; Gelblum, D. Y.; Wu, A. J.; Hellmann, M. D.; Rimner, A.; Paik, P. K.; Chaft, J. E.; more...
    Journal of Thoracic Oncology (2021)

    Fulltext@MSK | Save
  • Heart dose is a dosimetric predictor of overall survival in patients with NSCLC undergoing post-operative radiation therapy
    Meeting Abstract

    Shepherd, A.; Yu, A.; Al-Sadawi, M.; Peleg, A.; Iocolano, M.; Leeman, J.; Imber, B.; Wild, A.; Offin, M.; Chaft, J.; more...
    Journal of Thoracic Oncology (2021)

    Fulltext@MSK | Save